Eurofins Responds to Increased Demand For COVID-19 Testing at Schools With Cost-effective Testing Programmes for the Educational Sector
19 Octobre 2021 - 5:45PM
Business Wire
Regulatory News:
Easy, reliable, high quality and cost-effective testing for
SARS-CoV-2 (COVID-19) is critical to help reopen and keep open many
aspects of society and business sectors worldwide. Eurofins
(Paris:ERF) is working with schools and education authorities to
design and implement cost-effective solutions to test this
important part of our community regularly and reliably.
Since spring 2021, Eurofins has been supporting schools in
Europe and the USA through COVID-19 monitoring programmes, in
collaboration with local health and education authorities. Group
companies pioneered case studies, early in the pandemic, in schools
in the USA and Germany to assess the effectiveness of pooled PCR
testing. The findings of these studies have allowed Eurofins to
develop customer-focussed, cost-effective testing solutions for
schools and universities. Pooled testing is underpinned by the gold
standard of COVID-19 PCR testing, but significantly reduces the
cost of monitoring programmes by simultaneously testing a group, or
‘pool’, of samples to detect the presence of SARS-CoV-2. Such
pooled testing programmes can be replicated in other settings, such
as care facilities and workplaces.
These school monitoring programmes are effective and easy to
carry out and have been proven to:
- Quickly identify positive cases from symptomatic and
asymptomatic individuals to enable rapid isolation and contact
tracing.
- Increase confidence in in-person teaching among school staff
and parents.
- Distinguish between seasonal flu and COVID-19 infections and
avoid unnecessary isolation measures.
Having ramped up the necessary capacity, Eurofins intends to
continue to support communities around the world with innovative
and cost-effective COVID-19 testing solutions and expand its
partnerships within the education sector to facilitate schooling in
safe environments.
Since 2020, Eurofins has reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and services and has carried out over 30
million PCR tests in its own laboratories.
For more information, please visit SAFER@WORK TM
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing and
in agroscience Contract Research Organisation services. Eurofins is
one of the market leaders in certain testing and laboratory
services for genomics, discovery pharmacology, forensics, advanced
material sciences and in the support of clinical studies, as well
as having an emerging global presence in Contract Development and
Manufacturing Organisations. The Group also has a rapidly
developing presence in highly specialised and molecular clinical
diagnostic testing and in-vitro diagnostic products.
With 55,000 staff across a decentralised and entrepreneurial
network of 900 laboratories in over 50 countries, Eurofins offers a
portfolio of over 200,000 analytical methods to evaluate the
safety, identity, composition, authenticity, origin, traceability
and purity of a wide range of products, as well as providing
innovative clinical diagnostic testing services and in-vitro
diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020, Eurofins reacted quickly to meet the global challenge
of COVID-19, by creating the capacity to help over 20 million
patients monthly who may have been impacted by the pandemic with
our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 30 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211019005867/en/
Investor Relations Eurofins Scientific SE E-mail:
ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024